Previous 10 | Next 10 |
Reneo Pharmaceuticals press release (NASDAQ:RPHM): Q1 GAAP EPS of -$0.53 misses by $0.01. The company had $138.7 million in cash, cash equivalents and short-term investments as of March 31, 2022. For further details see: Reneo Pharmaceuticals GAAP EPS of -$0.53 misses by $0.01
IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the...
Reneo Pharmaceuticals press release (NASDAQ:RPHM): Q4 GAAP EPS of -$0.43 beats by $0.14. The company had $147.7 million in cash, cash equivalents and short-term investments as of December 31, 2021. For further details see: Reneo Pharmaceuticals GAAP EPS of -$0.43 beats by $0.14
IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for th...
Reneo Pharmaceuticals (NASDAQ:RPHM) appointed Michael Cruse as COO. Cruse most recently served as SVP of corporate operations at RPHM. Jennifer Lam has been appointed as principal financial and accounting officer. Lam currently serves as VP of finance and accounting at RPHM. For further det...
Michael P. Cruse appointed Chief Operating Officer Jennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the developme...
IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be hostin...
IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board o...
Reneo Pharmaceuticals (RPHM +26.8%) has added more than a quarter of value so far, propelling the micro-cap stock to record its sharpest intra-day gain since the company went public early this year. About 374.4K Reneo (NASDAQ:RPHM) shares have changed hands, indicating an over 11-fold rise in...
Reneo Pharmaceuticals (NASDAQ:RPHM): Q3 GAAP EPS of -$0.52 misses by $0.05. Press Release. For further details see: Reneo Pharmaceuticals EPS misses by $0.05
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...